<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02147015</url>
  </required_header>
  <id_info>
    <org_study_id>VIP</org_study_id>
    <nct_id>NCT02147015</nct_id>
  </id_info>
  <brief_title>Personalized Variable Versus Experiential or Fixed Dose Glucocorticoid Therapy in AECOPD</brief_title>
  <official_title>Personalized Variable Versus Experiential or Fixed Dose Corticosteroids Therapy in Hospitalized Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that in acute exacerbated Chronic Obstructive Pulmonary Disease (AECOPD),
      personalized variable dose glucocorticoid treatment will result in superior clinical outcome
      when compared to fixed or experiential dose therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with glucocorticoid for acute exacerbations of COPD results in the improvement of
      clinical outcomes. However, the optimal doses of glucocorticoid for each individual patient
      has not been determined. According to GOLD Report 2014, a dose of 40 mg prednisone per day
      for 5 days is recommended (Evidence B), although there are insufficient data to provide firm
      conclusions concerning the optimal duration of corticosteroid therapy of acute exacerbations
      of COPD. The purpose of the current study is to compare clinical outcomes of personalized or
      fixed or experiential dose of glucocorticoid in patients with acute exacerbations of COPD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>6 months</time_frame>
    <description>death from any cause;
admission to the intensive care unit;
readmission to the hospital because of COPD
the necessity to intensify pharmacologic treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospital costs</measure>
    <time_frame>up to 1 month</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Personalized variable dose of glucocorticoids arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of personalized variable dose of glucocorticoids according to a rating scale starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, Inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA), Long-Acting Muscarinic Antagonists(LAMA), short-acting beta2-agonist (SABA), and other physical treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experiential dose of glucocorticoids arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Use of glucocorticoids at doses according to normal clinical practice, together with other necessary treatments, including antibiotics, ICS, LABA, LAMA, SABA, and other physical treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed dose of glucocorticoids arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Use of fixed term of glucocorticoids (40mg) starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, ICS, LABA, LAMA, SABA, and other physical treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <arm_group_label>Personalized variable dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Experiential dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Fixed dose of glucocorticoids arm</arm_group_label>
    <other_name>methylprednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <arm_group_label>Personalized variable dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Experiential dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Fixed dose of glucocorticoids arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled corticosteroid (ICS)</intervention_name>
    <arm_group_label>Personalized variable dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Experiential dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Fixed dose of glucocorticoids arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long-Acting Muscarinic Antagonists(LAMA)</intervention_name>
    <arm_group_label>Personalized variable dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Experiential dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Fixed dose of glucocorticoids arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Short-acting beta2-agonist (SABA)</intervention_name>
    <arm_group_label>Personalized variable dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Experiential dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Fixed dose of glucocorticoids arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical treatments</intervention_name>
    <arm_group_label>Personalized variable dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Experiential dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Fixed dose of glucocorticoids arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>long-acting beta2-agonist (LABA)</intervention_name>
    <arm_group_label>Personalized variable dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Experiential dose of glucocorticoids arm</arm_group_label>
    <arm_group_label>Fixed dose of glucocorticoids arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Exacerbation of COPD as defined by the presence of at least 2 of the following: change
             in baseline dyspnea, cough, or sputum quantity or purulence.

        Exclusion Criteria:

          -  Signs of severe exacerbation (arterial pH &lt; 7.26 or PaCO2 &gt; 9.3 kPa)

          -  History of asthma

          -  Significant or unstable co-morbidity

          -  Participated in another study 4 weeks before admission

          -  Previously randomized to this study

          -  Known hypersensitivity to prednisolone

          -  Inability to give written informed consent

          -  Radiological diagnosis of pneumonia

          -  Estimated survival of less than 6 months due to severe comorbidity

          -  Use of glucocorticoid within 1 month before admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoqiang Cao, Medical Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daping Hospital, Third Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guoqiang Cao, Medical Doctor</last_name>
    <phone>86-23-68757781</phone>
    <email>cgq1963@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Li, Medical Doctor</last_name>
    <phone>86-23-68757793</phone>
    <email>lili10119@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Daping Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Zhou, Medical Doctor</last_name>
      <phone>86-23-68757001</phone>
    </contact>
    <investigator>
      <last_name>Guoqiang Cao, Medical Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999 Aug 7;354(9177):456-60.</citation>
    <PMID>10465169</PMID>
  </reference>
  <reference>
    <citation>Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010 Jun 16;303(23):2359-67. doi: 10.1001/jama.2010.796.</citation>
    <PMID>20551406</PMID>
  </reference>
  <reference>
    <citation>Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, Miedinger D, MÃ¼ller B, Scherr A, Schindler C, Stoeckli R, Viatte S, von Garnier C, Tamm M, Rutishauser J. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013 Jun 5;309(21):2223-31. doi: 10.1001/jama.2013.5023.</citation>
    <PMID>23695200</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2014</study_first_posted>
  <last_update_submitted>June 6, 2014</last_update_submitted>
  <last_update_submitted_qc>June 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Guoqiang Cao</investigator_full_name>
    <investigator_title>Vice Chair of Department of Respiratory Medicine</investigator_title>
  </responsible_party>
  <keyword>Acute Exacerbations</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Doses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Muscarinic Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

